College School of Biosystem and Biomedical Science of Health Science, Korea University, Seoul 02841, Korea.
Center for Functional Connectomics, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea.
Cells. 2019 Jun 9;8(6):562. doi: 10.3390/cells8060562.
Volume-regulated anion channels (VRACs) are involved in cellular functions such as regulation of cell volume, proliferation, migration, and cell death. Although leucine-rich repeat-containing 8A (LRRC8A) has been characterized as a molecular component of VRACs, here we show that Drosophila melanogaster tweety homologue 1 and 2 (TTYH1 and TTYH2) are critical for VRAC currents in cancer cells. LRRC8A-independent VRAC currents were present in the gastric cancer cell line SNU-601, but almost completely absent in its cisplatin-resistant derivative SNU-601-R10 (R10). The VRAC current in R10 was partially restored by treatment with trichostatin A (TSA), a histone deacetylase inhibitor. Based on microarray expression profiling of these cells, we selected two chloride channels, TTYH1 and TTYH2, as VRAC candidates. VRAC currents were completely absent from TTYH1- and TTYH2-deficient SNU-601 cells, and were clearly restored by expression of TTYH1 or TTYH2. In addition, we examined the expression of TTYH1 or TTYH2 in several cancer cell lines and found that VRAC currents of these cells were abolished by gene silencing of TTYH1 or TTYH2. Taken together, our data clearly show that TTYH1 and TTYH2 can act as LRRC8A-independent VRACs, suggesting novel therapeutic approaches for VRACs in cancer cells.
容积调节阴离子通道(VRAC)参与细胞功能,如细胞体积调节、增殖、迁移和细胞死亡。尽管富含亮氨酸重复序列 8A(LRRC8A)已被确定为 VRAC 的分子组成部分,但在这里我们表明,果蝇 tweety 同源物 1 和 2(TTYH1 和 TTYH2)是癌细胞中 VRAC 电流的关键。在胃癌细胞系 SNU-601 中存在 LRRC8A 非依赖性 VRAC 电流,但在其顺铂耐药衍生物 SNU-601-R10(R10)中几乎完全不存在。用组蛋白去乙酰化酶抑制剂 Trichostatin A(TSA)处理可部分恢复 R10 中的 VRAC 电流。基于这些细胞的微阵列表达谱分析,我们选择了两个氯离子通道 TTYH1 和 TTYH2 作为 VRAC 候选物。TTYH1 和 TTYH2 缺陷的 SNU-601 细胞中完全不存在 VRAC 电流,而表达 TTYH1 或 TTYH2 则明显恢复。此外,我们检查了几种癌细胞系中 TTYH1 或 TTYH2 的表达情况,发现这些细胞的 VRAC 电流被 TTYH1 或 TTYH2 的基因沉默所消除。总之,我们的数据清楚地表明,TTYH1 和 TTYH2 可以作为 LRRC8A 非依赖性 VRAC 发挥作用,为癌细胞中的 VRAC 提供了新的治疗方法。